BRIEF published on 06/14/2024 at 22:50, 1 year 7 months ago Reminder Notice of Annual General and Special Meeting for Shareholders of Theralase® Shareholders Theralase® Virtual Meeting AGSM Zoom Presentation
PRESS RELEASE published on 06/14/2024 at 22:45, 1 year 7 months ago Reminder Notice of Annual General and Special Meeting for Shareholders of Theralase(R) Theralase Technologies Inc. provides a reminder for its Annual General and Special Meeting to be held on June 19th, 2024, with a virtual Zoom presentation including a Q&A session for shareholders Annual General Meeting Shareholders Theralase Technologies Inc. AGSM Virtual Zoom Presentation
BRIEF published on 06/12/2024 at 13:05, 1 year 7 months ago Rutherrin® Increases Efficacy of Chemotherapy Cancer Treatment Chemotherapy Rutherrin® Multidrug Resistance Theralase® Technologies
PRESS RELEASE published on 06/12/2024 at 13:00, 1 year 7 months ago Rutherrin(R) Increases Efficacy of Chemotherapy Theralase Technologies announces preclinical success of Rutherrin® in enhancing chemotherapy efficacy and reducing multidrug resistance in cancer cells Cancer Treatment Theralase Technologies Rutherrin® Multidrug Resistance Chemotherapy Efficacy
BRIEF published on 06/10/2024 at 13:05, 1 year 7 months ago Ruvidar(TM) Enhances Efficacy of Cancer Drug Cancer Treatment Theralase Technologies Ruvidar(TM) BCG NMIBC
PRESS RELEASE published on 06/10/2024 at 13:00, 1 year 7 months ago Ruvidar(TM) Enhances Efficacy of Cancer Drug Theralase® Technologies Inc. announces breakthrough in cancer research by developing RuBCG compound to enhance efficacy of bladder cancer treatment. Preclinical results show promising potential Theralase Technologies Inc. Cancer Research RuBCG Compound Bladder Cancer Treatment Preclinical Results
BRIEF published on 06/06/2024 at 13:05, 1 year 7 months ago Theralase Successfully Destroys Lung Cancer Preclinical Study Theralase Technologies Lung Cancer Rutherrin®
PRESS RELEASE published on 06/06/2024 at 13:00, 1 year 7 months ago Theralase(R) Successfully Destroys Lung Cancer Theralase® Technologies Inc. announces preclinical success with Rutherrin® compound in targeting Non-Small Cell Lung Cancer. Results show improved tumour destruction and slower progression Theralase Technologies Inc. Cancer Treatment Preclinical Study NSCLC Rutherrin Compound
BRIEF published on 06/04/2024 at 13:05, 1 year 7 months ago Theralase® Technology Effective in Virus Inactivation Theralase Ruvidar Antiviral Research Virus Inactivation Heliyon
PRESS RELEASE published on 06/04/2024 at 13:00, 1 year 7 months ago Theralase(R) Technology Effective in Virus Inactivation Theralase Technologies Inc. announces successful inactivation of various viruses with lead compound RuvidarTM through peer-reviewed research. Potential for viral vaccine development highlighted Theralase Technologies Inc. RuvidarTM Peer-Reviewed Research Viral Inactivation Viral Vaccine Development
Published on 01/31/2026 at 03:15, 1 day 17 hours ago Empress Royalty Announces Grant Of Restricted Share Units
Published on 01/31/2026 at 01:40, 1 day 18 hours ago Star Copper Announces Grant of RSUs, Stock Options and PSUs
Published on 01/30/2026 at 23:00, 1 day 21 hours ago Avidian Gold Corp. Announces Director Resignation
Published on 02/01/2026 at 20:25, 8 minutes ago WHO Makes Historic Pivot to County-Level Governance, Validating "Bottom-Up" Climate-Health Model in Tropical Southern China
Published on 01/31/2026 at 15:54, 1 day 4 hours ago EQS-Adhoc: Wolford AG: Capital increase will not be implemented
Published on 01/31/2026 at 12:25, 1 day 8 hours ago JOHNNIE WALKER TOASTS MUSIC'S BIGGEST WEEKEND WITH THE GO GO HIGHBALL
Published on 01/31/2026 at 02:45, 1 day 17 hours ago CANADA BACKS NEW DEFENCE, SECURITY AND RESILIENCE BANK
Published on 01/30/2026 at 22:00, 1 day 22 hours ago Nebius Group N.V. announces date of fourth quarter and full year 2025 results and conference call
Published on 01/30/2026 at 17:45, 2 days 2 hours ago Schneider Electric launches a capital increase reserved for employees
Published on 01/29/2026 at 18:00, 3 days 2 hours ago GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 3 days 2 hours ago LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 3 days 2 hours ago Cegedim generated LFL revenue growth of 1.1% in 2025
